Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for Momenta, Inc
19.88
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 9.38 - 20.75
Open     -
Vol / Avg. 0.00/1.37M
Mkt cap 1.29B
P/E     -
Div/yield     -
EPS -1.78
Shares 64.71M
Beta 2.20
Inst. own 79%
Jul 29, 2015
Q2 2015 Momenta Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 11, 2015
Momenta Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 10:30AM EDT - Add to calendar
Jun 9, 2015
Momenta Pharmaceuticals Inc Annual Shareholders Meeting - 10:30AM EDT - Add to calendar
May 19, 2015
Momenta Pharmaceuticals Inc at UBS Global Healthcare Conference
May 13, 2015
Momenta Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Momenta Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 1, 2015
Q1 2015 Momenta Pharmaceuticals Inc Earnings Call
May 1, 2015
Q1 2015 Momenta Pharmaceuticals Inc Earnings Release
Apr 16, 2015
Momenta Pharmaceuticals Inc Announces FDA Approval of ANDA for GlatopaT Conference Call - Webcast
Mar 3, 2015
Momenta Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -255.51% -188.71%
Operating margin -257.85% -190.23%
EBITD margin - -173.58%
Return on average assets -34.01% -34.41%
Return on average equity -41.48% -41.41%
Employees 256 -
CDP Score - -

Address

675 W Kendall St
CAMBRIDGE, MA 02142-1110
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Momenta Pharmaceuticals, Inc. is a biotechnology company operating in three product areas: Complex Generics, Biosimilars and Novel Drugs. The Company’s approach is built around a complex systems analysis platform that it uses to obtain a detailed understanding of complex chemical and biologic systems, design product candidates, analyze sets of biological data to evaluate the biological function of its products and develop manufacturing processes that enable its products to be reliably produced. The Company uses its complex systems analysis platform to define the detailed structures present in these complex drugs. To demonstrate that the biological function of the Company’s generic replicates that of the brand, the Company utilizes its complex systems analysis platform to evaluate and compare multiple orthogonal sets of biologic data from in-vitro, in-vivo and ex-vivo models.

Officers and directors

James R. Sulat Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Craig A. Wheeler President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard P. Shea Chief Financial Officer, Senior Vice President
Age: 63
Bio & Compensation  - Reuters
Michael Franken M.D. President - Biosimilars Business, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Ganesh Venkataraman Kaundinya Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Bruce A. Leicher Senior Vice President, General Counsel, Secretary
Age: 59
Bio & Compensation  - Reuters
John E. Bishop Ph.D. Senior Vice President - Pharmaceutical Sciences
Age: 53
Bio & Compensation  - Reuters
James M. Roach M.D. Senior Vice President - Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 61
Bio & Compensation  - Reuters
Bruce L. Downey Independent Director
Age: 68
Bio & Compensation  - Reuters